Kenvue Inc. shares KVUE were cheered in their Wall Street debut Thursday, as the Johnson & Johnson JNJ spinoff, with consumer brands including Tylenol, Band-Aid and Listerine, saw it’s stock open 16.0% above its initial public offering price. Kenvue raised $3.8 billion as it said late Wednesday that it sold 172.
8 million shares in the IPO, up from previous expectations of 151.2 million shares, at $22 a share, which was at the higher end of the expected pricing range of between $20 and $23 a share. With 1.87 billion shares outstanding after the IPO, the pricing values the company at $41.08 billion. The stock’s first trade...
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: